Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AcSé-ESMART enasidenib arm in relapsed or refractory pediatric cancers
NL-OMON60846Phase 2Recruiting
- Sponsor
- Gustave Roussy
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enasidenib in childhood cancer, Non-hematologic malignancy and hematopoietic malignancies, sponsored by Gustave Roussy. Primary endpoint: Recommended phase II dose. Started Apr 2018; status: recruiting.
02
Drugs
enasidenib
03
Conditions
childhood cancerNon-hematologic malignancyhematopoietic malignancies
Beyond the preview
Go deeper on NL-OMON60846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60846.